Evidence Gaps

What do systematic reviews say?

1 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 40%Moderate 3 · 60%High 0 · 0%

Delayed‐release mesalamine (3 ‐ 4.5 g/day) vs corticosteroids

Induction of remission (CDAI < or =150 with or without decrease of at least 60 points) · patients with Induction of remission or response in Crohn's disease

Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).

5 findings from 1 review

Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.04 [0.79, 1.36]
3 studies · 178 participants
Moderate
Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.95 [0.49, 1.85]
1 study · 50 participants
Low
Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1 [0.61, 1.64]
1 study · 50 participants
Moderate

Show 2 more findings

Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 1.26 [0.82, 1.92]
1 study · 44 participants
Moderate
Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.67 [0.3, 1.46]
1 study · 34 participants
Low